AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Immunitybio Inc (NASDAQ:IBRX)
3.045 USD
-0.315 9.375%Sponsored Reports
Loading...
| Previous Close (in USD) | 3.36 |
|---|---|
| Change | -0.315 9.375% |
| 52 W H/L (in USD) | 10.530/1.250 |
| EBITDA (in USD) | -326.593M |
| PE Ratio | -- |
| Volume | 6854322 |
| Diluted Eps TTM | -1.08 |
| Total Assets (in USD) | 504.452M |
|---|---|
| Total Liabilities (in USD) | 1090.389M |
| Revenue TTM (in USD) | 0.302M |
| Cash (in USD) | 265.453M |
| Market Cap (in USD) | 4,509.023 M |
| Revenue Per Share TTM | 0.001 |
| Gross Profit TTM (in USD) | 0.24M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Immunitybio Inc
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
Employees: 628
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Patrick Soon-Shiong FACS, FRCS (C), M.Sc. | Exec. Chairman, Global Chief Scientific & Medical Officer | 1953 |
| 2. | Mr. Richard Gerald Adcock | Pres, CEO & Director | 1969 |
| 3. | Mr. David C. Sachs | CFO, Principal Financial Officer & Principal Accounting Officer | 1978 |
| 4. | Dr. Leonard S. Sender M.D. | Chief Operating Officer | NA |
| 5. | Mr. Jason R. Liljestrom | Gen. Counsel & Corp. Sec. | 1983 |
| 6. | Ms. Sarah Singleton | Chief Communications Officer | NA |
| 7. | Dr. Sandeep K. Reddy M.D. | Chief Medical Officer | NA |
| 8. | Dr. Barry J. Simon M.D. | Chief Corp. Affairs Officer & Director | 1965 |
| 9. | Dr. Hans Georg Klingemann M.D., Ph.D. | Chief Science Officer of Cellular | 1950 |
| 10. | Ms. Helen Luu | Chief Commercial Officer | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.720 1.026% | 70.17 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.980 1.404% | 68.8 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.590 1.510% | 504.79 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+3.800 0.598% | 638.01 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -583.892M | -417.286M | -349.839M | -226.033M | -160.263M |
| Minority Interest | 0.745M | -0.753M | -3.058M | 1.318M | 3.654M |
| Net Income | -583.196M | -417.32M | -349.848M | -224.187M | -160.158M |
| Selling General Administrative | 122.725M | 102.708M | 135.256M | 27.254M | 18.065M |
| Gross Profit | -17.89M | -23.952M | 0.934M | -8.542M | -6.81M |
| Reconciled Depreciation | 19.174M | 18.26M | 14.238M | 12.739M | 14.042M |
| Ebit | -361.364M | -351.298M | -330.28M | -220.88M | -156.251M |
| Ebitda | -342.852M | -343.978M | -316.304M | -195.128M | -139.976M |
| Depreciation And Amortization | 18.512M | 7.32M | 13.976M | 25.752M | 16.275M |
| Operating Income | -361.364M | -351.298M | -330.28M | -220.88M | -156.251M |
| Other Operating Expenses | 361.986M | 350.857M | 331.214M | 210.825M | 158.453M |
| Interest Expense | 129.198M | 63.515M | 14.849M | 9.074M | 5.92M |
| Tax Provision | 0.034M | 0.034M | 0.009M | 0.005M | -0.097M |
| Interest Income | 2.001M | 2.708M | 0.836M | 1.183M | 1.62M |
| Net Interest Income | -123.633M | -60.807M | -14.013M | -7.349M | -3.156M |
| Income Tax Expense | -0.04M | 0.034M | 0.009M | -1.846M | -0.105M |
| Total Revenue | 0.622M | 0.24M | 0.934M | 0.605M | 2.202M |
| Total Operating Expenses | 343.474M | 350.857M | 331.214M | 210.825M | 158.453M |
| Cost Of Revenue | 18.512M | 24.192M | - | 9.147M | 9.012M |
| Total Other Income Expense Net | -222.528M | -65.988M | -19.559M | -5.153M | -4.012M |
| Net Income From Continuing Ops | -458.764M | -417.32M | -349.848M | -92.383M | -160.158M |
| Net Income Applicable To Common Shares | - | -416.567M | -346.79M | -129.041M | -91.423M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 504.452M | 362.356M | 468.91M | 221.381M | 143.123M |
| Intangible Assets | 17.093M | 20.003M | 1.42M | 1.463M | - |
| Other Current Assets | 24.454M | 5.149M | 15.898M | 13.649M | 3.802M |
| Total Liab | 1090.389M | 812.176M | 712.823M | 339.871M | 22.444M |
| Total Stockholder Equity | -586.987M | -447.327M | -242.173M | -119.808M | 120.679M |
| Other Current Liab | 42.205M | 45.294M | 55.33M | 51.609M | 9.81M |
| Common Stock | 0.067M | 0.042M | 0.04M | 0.038M | 0.01M |
| Capital Stock | 0.067M | 0.042M | 0.04M | 0.038M | - |
| Retained Earnings | -2961.684M | -2378.488M | -1961.921M | -1615.131M | -662.191M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 6.629M | 6.379M | 7.606M | 7.011M |
| Cash | 265.453M | 104.641M | 181.101M | 34.915M | 15.508M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 58.283M | 500.861M | 368.995M | 68.134M | 11.559M |
| Current Deferred Revenue | 0.1M | - | - | - | - |
| Net Debt | 618.224M | 619.132M | 464.563M | 240.632M | -0.66M |
| Short Term Debt | 6.783M | 434.551M | 302.247M | 5.015M | - |
| Short Long Term Debt | - | 431.901M | 299.236M | - | - |
| Short Long Term Debt Total | 883.677M | 723.773M | 645.664M | 275.547M | 14.848M |
| Other Stockholder Equity | 2374.62M | 1930.936M | 1719.704M | 1495.163M | 801.467M |
| Property Plant Equipment | - | 143.659M | 82.863M | 28.959M | 27.776M |
| Total Current Assets | 294.084M | 140.577M | 334.347M | 111.713M | 55.757M |
| Long Term Investments | 0.891M | 0.84M | 0.822M | 11.397M | - |
| Short Term Investments | 1.009M | 2.543M | 136.015M | 61.146M | 36.144M |
| Net Receivables | 3.168M | 1.89M | 1.333M | 2.003M | 0.303M |
| Long Term Debt | 681.537M | 241.271M | 306.349M | 254.353M | - |
| Inventory | - | 26.354M | - | - | - |
| Accounts Payable | 9.195M | 21.016M | 11.418M | 11.51M | 1.749M |
| Accumulated Other Comprehensive Income | 0.01M | 0.183M | 0.004M | 0.122M | -18.607M |
| Non Currrent Assets Other | 2.488M | 6.629M | 7.201M | 7.079M | 5.883M |
| Non Current Assets Total | 210.368M | 221.779M | 134.563M | 109.668M | 87.366M |
| Capital Lease Obligations | 45.186M | 50.601M | 40.079M | 21.194M | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 126.688M | -71.821M | -0.193M | -0.499M | 35.026M |
| Total Cashflows From Investing Activities | 27.297M | -84.886M | -1.371M | -6.315M | 25.68M |
| Total Cash From Financing Activities | 233.613M | 505.443M | 150.675M | 114.279M | -0.771M |
| Net Income | -417.32M | -349.848M | -224.187M | -160.158M | -96.226M |
| Change In Cash | -76.315M | 146.186M | -40.886M | -19.299M | -7.051M |
| Begin Period Cash Flow | 181.28M | 35.094M | 75.98M | 95.279M | 24.051M |
| End Period Cash Flow | 104.965M | 181.28M | 35.094M | 75.98M | 17M |
| Total Cash From Operating Activities | -337.509M | -274.419M | -171.724M | -152.109M | -63.381M |
| Depreciation | 18.26M | 14.238M | 12.739M | 14.042M | 9.555M |
| Other Cashflows From Investing Activities | -21.229M | 20.498M | -17.95M | 25.638M | 70.203M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | 60.501M | 171.426M | 86.975M | -2.501M | -0.228M |
| Other Cashflows From Financing Activities | 173.244M | 340.913M | 64.373M | 86.78M | -0.066M |
| Capital Expenditures | 99.391M | 33.563M | 1.669M | 4.287M | 13.102M |
| Change In Working Capital | -8.001M | -19.112M | 16.36M | -15.636M | -50.078M |
| Other Non Cash Items | 29.377M | 23.13M | 24.115M | 6.23M | 50.484M |
| Free Cash Flow | -436.9M | -307.982M | -173.393M | -156.396M | -76.483M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | SPDR® S&P Biotech ETF | 10 months ago | 10173961 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 10 months ago | 4199294 |
| 3. | Vanguard Small Cap Index | 10 months ago | 3396317 |
| 4. | iShares Russell 2000 ETF | 10 months ago | 3115447 |
| 5. | Vanguard Institutional Extnd Mkt Idx Tr | 10 months ago | 2290978 |
| 6. | Vanguard Small Cap Growth Index Inv | 10 months ago | 1919270 |
| 7. | Fidelity Small Cap Index | 1 year ago | 1354964 |
| 8. | JPM Thematics Genetic Thrps C2 Acc USD | 10 months ago | 1097243 |
| 9. | Direxion Daily S&P Biotech Bull 3X ETF | 10 months ago | 1023817 |
| 10. | iShares Russell 2000 Growth ETF | 10 months ago | 909447 |
| 11. | Fidelity Extended Market Index | 11 months ago | 880515 |
| 12. | State St Russell Sm/Mid Cp® Indx NL Cl C | 10 months ago | 798274 |
| 13. | Schwab US Small-Cap ETF™ | 10 months ago | 726971 |
| 14. | Invesco Dorsey Wright SmallCap Momt ETF | 10 months ago | 677358 |
| 15. | Invesco Dorsey Wright Healthcare MomtETF | 10 months ago | 536552 |
| 16. | First Trust Small Cap Core AlphaDEX® ETF | 10 months ago | 524551 |
| 17. | State St Russell Sm Cap® Indx SL Cl I | 10 months ago | 504752 |
| 18. | Vanguard Russell 2000 ETF | 10 months ago | 499269 |
| 19. | Vanguard Health Care ETF | 10 months ago | 452238 |
| 20. | Fidelity Nasdaq Composite Index | 11 months ago | 397931 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Group Inc | 11 months ago | 13539590 |
| 2. | BlackRock Inc | 1 year ago | 10710179 |
| 3. | State Street Corporation | 1 year ago | 9470909 |
| 4. | Geode Capital Management, LLC | 1 year ago | 3379464 |
| 5. | Goldman Sachs Group Inc | 1 year ago | 2557276 |
| 6. | Credit Suisse First Boston (CSFB) | 11 months ago | 1548826 |
| 7. | JPMorgan Chase & Co | 1 year ago | 1422212 |
| 8. | Northern Trust Corp | 1 year ago | 1357059 |
| 9. | Rafferty Asset Management, LLC | 11 months ago | 1310390 |
| 10. | Charles Schwab Investment Management Inc | 11 months ago | 1171212 |
| 11. | Citigroup Inc | 11 months ago | 1128446 |
| 12. | Perceptive Advisors LLC | 11 months ago | 1052887 |
| 13. | Sheets Smith Wealth Management | 11 months ago | 945720 |
| 14. | Bank of America Corp | 1 year ago | 891815 |
| 15. | JANE STREET GROUP, LLC | 1 year ago | 821643 |
| 16. | Allen Holding Inc | 11 months ago | 687571 |
| 17. | Amvescap Plc. | 1 year ago | 641363 |
| 18. | Morgan Stanley - Brokerage Accounts | 1 year ago | 599718 |
| 19. | Putnam Investments, LLC., a Franklin Templeton company | 1 year ago | 534201 |
| 20. | Nuveen Asset Management, LLC | 1 year ago | 522477 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
